Sponsored by The Binding Site
The serum FLC assay is a quantitative and fully automated approach to measure free lambda and free kappa light chain levels in the serum. With more than 3000 articles published so far, this assay has been proven as being a major breakthrough for the diagnosis and monitoring of multiple myeloma and other monoclonal gammopathies. In conjunction with other methods used in the diagnosis of these malignancies, the serum Free Light Chain assay is now part of the battery of tests recommended by all guidelines for diagnosis, monitoring and prognosis. However, knowing limitations and how to interpret results on the Optilite instrument are keys for an optimal utilization of the assay and result reporting.
At the end of this session you will be able to:
- Understand the basic concepts related to Myeloma and other monoclonal gammopathies
- Learn the current methods routinely used in the laboratory to help the diagnosis of Multiple Myeloma
- Describe the serum free light chain assay, its limitations and its interpretation
- Overview the guidelines recommendations, clinical benefits & applications of the serum FLC assay in the management of multiple myeloma patients
Speaker: Frank Courjal, PhD